Adjust to target in type 2 diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

Diabetes Care

Volumn 31, Issue 7, 2008, Pages 1305-1310

  Bergenstal, Richard M ^a   Johnson, Mary ^a   Powers, Margaret A ^a   Wynne, Alan ^b   Vlajnic, Aleksandra ^c   Hollander, Priscilla ^d   Rendell, Marc ^e  

^a International Diabetes   (United States)

^b Pediatric Cardiology   (United States)

^c SANOFI   (France)

^d Baylor Endocrine Center   (United States)

^e Creighton Diabetes Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; LIPID; METFORMIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ALGORITHM; ARTICLE; BODY MASS; CARBOHYDRATE INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; CARBOHYDRATE DIET; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EATING; METABOLISM; MIDDLE AGED; RACE; UNITED STATES;

ADULT; AGED; ALGORITHMS; BLOOD GLUCOSE; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; UNITED STATES;

EID: 49649123535     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-2137     Document Type: Article

References (25)

1. Home P: Contributions of basal and postprandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989-998, 2005
2. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen M-R: What does postprandial hyperglycaemia mean? Dia- bet Med 21:208-213, 2004
3. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1-7, 2005
4. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, UK Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
5. Gerich JE: Novel insulins: expanding options in diabetes management. Am J Med 113:308-316, 2002
6. DreyerM, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R: Ef?-cacy and safety of insulin glulisine in pa-tients with type 1 diabetes. Horm MetabRes 37:702-707, 2005
7. Gross TM, Kayne D, King A, Rother C,Juth S: A bolus calculator is an effectivemeans of controlling postprandial glyce-mia in patients on insulin pump therapy.Diabetes Technol Ther 5:365-369, 2003
8. Kalergis M, Pacaud D, Strychar I, MeltzerS, Jones PJ, Yale JF: Optimizing insulindelivery: assessment of three strategies inintensive diabetes management. Diabetes Obes Metab 2:299-305, 2000
9. DAFNE Study Group: Training in ?exi-ble, intensive insulin management to en-able dietary freedomin peoplewith type 1diabetes: dose adjustment for normal eat-ing (DAFNE) randomised controlled trial. BMJ 325:746-751, 2002
10. Peragallo-Dittko V (Ed.): A Core Curricu- lum for Diabetes Education. 4th ed. Chi- cago, American Association of Diabetes Educators, 2001
11. Kaufman FR, Halvorson M, Carpenter S:Use of a plastic insulin dosage guide to correct blood glucose levels out of the tar-get range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care 22:1252-1257, 1999
12. Rickheim P, Flader J, Carstensen KM:Type 2 Diabetes BASICS. 2nd ed. Minne- apolis, International Diabetes Center,Type 2 Diabetes BASICS. 2nd ed. Minne- apolis, International Diabetes Center,2004
13. American Association of Clinical Endocri- nologists/American College of Endocri- nology: The American Association of Clinical Endocrinologists medical guide-lines for the management of diabetes mel- litus: the AACE system of intensive diabetes self-management-2002 up-date. Endocr Pract 8:41-82, 2002
14. American Diabetes Association: Stan- dards ofmedical care in diabetes. Diabetes Care 29 (Suppl. 1):S4-S42, 2006
15. Raskin P, Klaff L, Bergenstal R, Halle JP,Donley D, Mecca T: A 16-week compari- son of the novel insulin analog insulin glargine (HOE 901) and NPH human in- sulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666-1671, 2000
16. De Leeuw I, Vague P, Selam JL, Skeie S,Lang H, Draeer E, Elte JWF: Insulin det- emir used in basal-bolus therapy in peo- ple with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months incomparison toNPHinsulin. Diabetes Obes Metab 7:73-82, 2005
17. Holman RR, Thorne KI, Farmer AJ, Da- vies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 1716-1730,2007
18. Garg SK, Rosenstock J, Ways K: Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 11:11-17, 2005
19. Dailey G, Rosenstock J, Moses RG, Ways K: Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27:2363-2368,2004
20. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S: Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Diabetes Care 31:20-25, 2008
21. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of micro- vascular complications of diabetes melli- tus. NEnglJMed 329:304-309, 1993
22. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of the long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
23. Ohkubo Y, Kishikawa H, Araki E, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic micro- vascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995
24. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sul- phonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
25. Buse JB: Should postprandial glucose be routinely measured and treated to a particular target? No! Diabetes Care 26:16151618, 2003